Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Wenying Yang, Dalong Zhu, Shenglian Gan, Xiaolin Dong, Junping Su, Wenhui Li, Hongwei Jiang, Wenjuan Zhao, Minxiu Yao, Weihong Song, Yibing Lu, Xiuzhen Zhang, Huifang Li, Guixia Wang, Wei Qiu, Guoyue Yuan, Jianhua Ma, Wei Li, Ziling Li, Xiaoyue Wang, Jiao'e Zeng, Zhou Yang, Jingdong Liu, Yongqian Liang, Song Lu, Huili Zhang, Hui Liu, Ping Liu, Kuanlu Fan, Xiaozhen Jiang, Yufeng Li, Qing Su, Tao Ning, Huiwen Tan, Zhenmei An, Zhaoshun Jiang, Lijun Liu, Zunhai Zhou, Qiu Zhang, Xuefeng Li, Zhongyan Shan, Yaoming Xue, Hong Mao, Lixin Shi, Shandong Ye, Xiaomei Zhang, Jiao Sun, Ping Li, Tao Yang, Feng Li, Jingna Lin, Zhinong Zhang, Ying Zhao, Ruonan Li, Xiaohui Guo, Qi Yao, Weiping Lu, Shen Qu, Hongmei Li, Liling Tan, Wenbo Wang, Yongli Yao, Daoxiong Chen, Yulan Li, Jialin Gao, Wen Hu, Xiaoqiang Fei, Tianfeng Wu, Song Dong, Wenlong Jin, Chenzhong Li, Dong Zhao, Bo Feng, Yu Zhao, Yi Zhang, Xiaoying Li, Li Chen, Wenying Yang, Dalong Zhu, Shenglian Gan, Xiaolin Dong, Junping Su, Wenhui Li, Hongwei Jiang, Wenjuan Zhao, Minxiu Yao, Weihong Song, Yibing Lu, Xiuzhen Zhang, Huifang Li, Guixia Wang, Wei Qiu, Guoyue Yuan, Jianhua Ma, Wei Li, Ziling Li, Xiaoyue Wang, Jiao'e Zeng, Zhou Yang, Jingdong Liu, Yongqian Liang, Song Lu, Huili Zhang, Hui Liu, Ping Liu, Kuanlu Fan, Xiaozhen Jiang, Yufeng Li, Qing Su, Tao Ning, Huiwen Tan, Zhenmei An, Zhaoshun Jiang, Lijun Liu, Zunhai Zhou, Qiu Zhang, Xuefeng Li, Zhongyan Shan, Yaoming Xue, Hong Mao, Lixin Shi, Shandong Ye, Xiaomei Zhang, Jiao Sun, Ping Li, Tao Yang, Feng Li, Jingna Lin, Zhinong Zhang, Ying Zhao, Ruonan Li, Xiaohui Guo, Qi Yao, Weiping Lu, Shen Qu, Hongmei Li, Liling Tan, Wenbo Wang, Yongli Yao, Daoxiong Chen, Yulan Li, Jialin Gao, Wen Hu, Xiaoqiang Fei, Tianfeng Wu, Song Dong, Wenlong Jin, Chenzhong Li, Dong Zhao, Bo Feng, Yu Zhao, Yi Zhang, Xiaoying Li, Li Chen

Abstract

Metformin, the first-line therapy for type 2 diabetes (T2D), decreases hepatic glucose production and reduces fasting plasma glucose levels. Dorzagliatin, a dual-acting orally bioavailable glucokinase activator targeting both the pancreas and liver glucokinase, decreases postprandial glucose in patients with T2D. In this randomized, double-blind, placebo-controlled phase 3 trial, the efficacy and safety of dorzagliatin as an add-on therapy to metformin were assessed in patients with T2D who had inadequate glycemic control using metformin alone. Eligible patients with T2D (n = 767) were randomly assigned to receive dorzagliatin or placebo (1:1 ratio) as an add-on to metformin (1,500 mg per day) for 24 weeks of double-blind treatment, followed by 28 weeks of open-label treatment with dorzagliatin for all patients. The primary efficacy endpoint was the change in glycated hemoglobin (HbA1c) levels from baseline to week 24, and safety was assessed throughout the trial. At week 24, the least-squares mean change from baseline in HbA1c (95% confidence interval (CI)) was -1.02% (-1.11, -0.93) in the dorzagliatin group and -0.36% (-0.45, -0.26) in the placebo group (estimated treatment difference, -0.66%; 95% CI: -0.79, -0.53; P < 0.0001). The incidence of adverse events was similar between groups. There were no severe hypoglycemia events or drug-related serious adverse events in the dorzagliatin and metformin combined therapy group. In patients with T2D who experienced inadequate glycemic control with metformin alone, dorzagliatin resulted in effective glycemic control with good tolerability and safety profile ( NCT03141073 ).

Conflict of interest statement

L.Chen, Y.Zhao and Y.Zhang are employees of Hua Medicine. W.Yang, D.Zhu and X.Li have served on the Diabetes Advisory Board for Hua Medicine. The remaining authors declare no competing interests.

© 2022. The Author(s).

Figures

Fig. 1. DAWN study patient disposition.
Fig. 1. DAWN study patient disposition.
DAWN study patient disposition flow diagram for the entire trial. Note that ten patients did not meet the inclusion and exclusion criteria but were included in the run-in period. In total, 767 patients were randomized, and 766 patients who took at least one dose of the study drug were included in the SS. The FAS included 751 patients who took at least one dose of the study drug and had at least one post-treatment measurement of the primary endpoint during the double-blind treatment period. Two patients did not meet the criteria for randomization but were randomized, one of whom was included in the FAS and the other was not, as this patient did not take at least one dose of the study drug.
Fig. 2. Primary and secondary efficacy endpoints.
Fig. 2. Primary and secondary efficacy endpoints.
a, The primary endpoint: LS mean changes in the HbA1c level from baseline to week 24 in patients who received either dorzagliatin and metformin or placebo and metformin. The ETD and corresponding 95% CI were estimated using, in the FAS, an MMRM without missing value imputation (dorzagliatin, n = 374; placebo, n = 374) (P < 0.0001). b, The mean HbA1c level recorded at each visit over 24 weeks in patients who received either dorzagliatin and metformin or placebo and metformin. c, The LS mean change in 2h-PPG levels from baseline. ETD and 95% CI were estimated in the FAS using an MMRM (dorzagliatin, n = 360; placebo, n = 355). d, The LS mean change in FPG from baseline. ETD and 95% CI were estimated in the FAS using an MMRM (dorzagliatin, n = 374; placebo, n = 374). e, The mean HbA1c levels measured at each visit over 52 weeks. The FAS comprised all randomized patients who took at least one dose of the study drug and had at least one post-treatment measurement of the primary endpoint during the double-blind treatment period. All statistical tests were two-sided at a significance level of 0.05, and no adjustments were made for multiplicity. Data in a, c and d are presented as LS mean ± s.e.; data in b and e are presented as mean ± s.e. Met: metformin.
Extended Data Fig. 1
Extended Data Fig. 1
DAWN study design.

References

    1. International Diabetes Federation. IDF Diabetes Atlas 10th edn (International Diabetes Federation, 2021).
    1. American Diabetes Association Professional Practice Committee et al. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care45, S125–S143 (2022)..
    1. Cosentino F, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2020;41:255–323. doi: 10.1093/eurheartj/ehz486.
    1. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–1585. doi: 10.1007/s00125-017-4342-z.
    1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK prospective diabetes study (UKPDS) group. JAMA. 1999;281:2005–2012. doi: 10.1001/jama.281.21.2005.
    1. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32:S151–S156. doi: 10.2337/dc09-S301.
    1. Matschinsky FM, Wilson DF. The central role of glucokinase in glucose homeostasis: a perspective 50 years after demonstrating the presence of the enzyme in islets of Langerhans. Front. Physiol. 2019;10:148. doi: 10.3389/fphys.2019.00148.
    1. Lenzen S. A fresh view of glycolysis and glucokinase regulation: history and current status. J. Biol. Chem. 2014;289:12189–12194. doi: 10.1074/jbc.R114.557314.
    1. Matschinsky FM. Regulation of pancreatic β-cell glucokinase: from basics to therapeutics. Diabetes. 2002;51:S394–S404. doi: 10.2337/diabetes.51.2007.S394.
    1. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem. J. 2008;414:1–18. doi: 10.1042/BJ20080595.
    1. Chen L, Zhang J, Yang R, Feng L. Glucokinase activator dorzagliatin (HMS5552) regulates GLP-1 release in T2D patients and is synergistic with sitagliptin and empagliflozin in optimizing beta-cell function. Diabetes. 2021;70:117-LB. doi: 10.2337/db21-117-LB.
    1. Li C, et al. Regulation of glucagon secretion in normal and diabetic human islets by γ-hydroxybutyrate and glycine. J. Biol. Chem. 2013;288:3938–3951. doi: 10.1074/jbc.M112.385682.
    1. Haeusler RA, et al. Decreased expression of hepatic glucokinase in type 2 diabetes. Mol. Metab. 2014;4:222–226. doi: 10.1016/j.molmet.2014.12.007.
    1. Froguel P, et al. Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N. Engl. J. Med. 1993;328:697–702. doi: 10.1056/NEJM199303113281005.
    1. Xu H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study. Drug Des. Devel. Ther. 2016;10:1619–1626.
    1. Zhu XX, et al. Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: a 28-day treatment study using biomarker-guided patient selection. Diabetes Obes. Metab. 2018;20:2113–2120. doi: 10.1111/dom.13338.
    1. Zhu DL, et al. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol. 2018;6:627–636. doi: 10.1016/S2213-8587(18)30105-0.
    1. Bonadonna RC, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J. Clin. Endocrinol. Metab. 2010;95:5028–5036. doi: 10.1210/jc.2010-1041.
    1. Grimsby J, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003;301:370–373. doi: 10.1126/science.1084073.
    1. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat. Rev. Drug Discov. 2009;8:399–416. doi: 10.1038/nrd2850.
    1. Zhi J, Zhai S. Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus. J. Clin. Pharmacol. 2016;56:231–238. doi: 10.1002/jcph.589.
    1. Wilding JP, Leonsson-Zachrisson M, Wessman C, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes. Metab. 2013;15:750–759. doi: 10.1111/dom.12088.
    1. Kiyosue A, Hayashi N, Komori H, Leonsson-Zachrisson M, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2013;15:923–930. doi: 10.1111/dom.12100.
    1. Amin NB, et al. Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes. Metab. 2015;17:751–759. doi: 10.1111/dom.12474.
    1. Katz L, et al. AMG 151 (ARRY-403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Diabetes Obes. Metab. 2016;18:191–195. doi: 10.1111/dom.12586.
    1. Meininger GE, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011;34:2560–2566. doi: 10.2337/dc11-1200.
    1. Chen L, Shan Y, Jin X, Lv X. Dorzagliatin differentiates from early generation of glucokinase activators: an enzyme kinetics study. Diabetes. 2019;68:1151-P. doi: 10.2337/db19-1151-P.
    1. SEED Study Group. Dorza gliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. (in the press).
    1. Chen L, Zhao G, Ren S, Zhang YI, Du D. No drug–drug interaction between dorzagliatin and metformin in type 2 diabetes patients. Diabetes. 2018;67:2310-PUB. doi: 10.2337/db18-2310-PUB.
    1. Yang W, Weng J. Early therapy for type 2 diabetes in China. Lancet Diabetes Endocrinol. 2014;2:992–1002. doi: 10.1016/S2213-8587(14)70136-6.
    1. Sharma R, et al. Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator. Drug Metab. Dispos. 2014;42:1926–1939. doi: 10.1124/dmd.114.060087.
    1. Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus. (2021).
    1. MedDRA Maintenance and Support Services Organization. Introductory Guide to MedDRA Version 23.0. (2022).

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe